JCR Pharmaceuticals Co., Ltd.
Domestic Development Plan for Duchenne Muscular Dystrophy Treatment｜July 2026
JCR Pharma announces its domestic development plan for the Duchenne Muscular Dystrophy treatment drug givinostat, aiming to submit for approval within 2026 and to commence sales within 2027.
Key Figures
- Scheduled year for manufacturing and sales approval application for this drug: within 2026
- Scheduled year for sales start: within 2027
- Impact on consolidated earnings for the current period (ending March 2027): minimal
AI要約
Performance Overview
JCR Pharma is advancing the domestic development of the histone deacetylase (HDAC) inhibitor givinostat, planning to submit for manufacturing and sales approval within 2026 and aiming for sales launch within 2027. The drug has already been approved overseas, and clinical trials are progressing in Japan. The impact on this fiscal year's performance is expected to be minimal.
Future Outlook
The company aims to leverage overseas clinical data to develop strategies that deliver the treatment early to Japanese DMD patients. Toward approval and sales start in 2027, R&D will be promoted to provide new treatment options for unmet medical needs in DMD.
JCR Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
